Oslo, Norway, November 6, 2024 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced new findings related to
its APC-targeted inverse vaccine platform's efficacy in treating autoimmune
disease at the annual PEGS Europe conference in Barcelona.

The data presented emphasize the role of antigen-presenting cell (APC) targeting
in achieving therapeutic effectiveness, particularly in Experimental Autoimmune
Encephalomyelitis (EAE), a mouse model of human multiple sclerosis (MS).
Findings from both therapeutic and preventive applications support the
platform's potential in providing targeted, effective treatment for MS, an
autoimmune disease that affects approximately 2.8 million people worldwide, with
a high annual economic burden and a significant unmet medical need for new
treatments.

Nykode's latest data confirm that APC targeting by the inverse vaccine is
essential for achieving effective therapeutic outcomes, demonstrating superior
efficacy over a non-targeted vaccine or antigen alone. When applied
therapeutically, a new version of Nykode's inverse vaccine provides robust
disease protection in a relapsing-remitting EAE model which better reflect the
relapsing-remitting disease in human MS. This result builds upon prior findings
and includes efficacy of an alternative central nervous system autoantigen,
broadening the inverse vaccine's potential applicability in MS treatment.
Aligned with these outcomes, mice treated with the Nykode inverse vaccine
exhibit a marked reduction in disease-associated inflammatory cytokine release
following disease induction. This reduction aligns with mitigated disease
severity and inflammation, highlighting the therapeutic potential of the Nykode
inverse vaccine in immune disorders. 

"These data provide valuable insights into the role of APC-targeted vaccines in
delivering effective therapeutic responses in different EAE models, relevant to
the clinical treatment of MS and supports the broader potential of our
technology in inducing tolerance in multiple settings," said Agnete Fredriksen,
Chief Scientific Officer and Co-founder of Nykode. "We are pleased to share
these findings at PEGS Europe and to further explore APC-targeted approaches for
autoimmune diseases."

 

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to antigen presenting cells (APC), employed with
their cancer vaccines to induce a broad, strong and long-lasting antigen
specific immune response, which correlates with clinical responses in cancer
patients.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies, which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer.
VB10.16 is being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen
vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company's partnerships include Genentech within oncology, and a multi-target
collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse
vaccine platform for the potential use in autoimmune disorders, organ transplant
rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway